Boston Scientific has announced that it will begin a limited launch of its enhanced ACURATE neo2 Aortic Valve System in Europe. The new system utilises transcatheter aortic valve implantation (TAVI) technology and builds on the original ACURATE neo’s clinical performance.
The ACURATE neo2 is designed to restore function and blood flow to severely narrowed aortic valves, with the new system featuring annular sealing technology which helps the device conform to irregular, calcified anatomies, while reducing paravalvular regurgitation or leaking.
It also features a delivery system which simplifies access to smaller and complex vessels at entry site, while allowing for accurate valve positioning. The top-down deployment mechanism also supports stable placement and release.
Seeking to improve on the original system, the new platform has expanded indication for aortic stenosis patients considered by their heart team to be appropriate candidates for the therapy.
Boston Scientific President of Interventional Cardiology Joe Fitzgerald said: “We believe having this differentiated valve with the enhanced sealing technology will further drive favorable market experience and growth.”
“Combined with the LOTUS Edge™ Aortic Valve System and SENTINEL™ Cerebral Protection System to protect the brain against the risk of TAVI-related stroke, the ACURATE neo2 valve represents the natural evolution of our complementary dual-valve TAVI toolkit that covers the needs of a wide range of patient cases.”
Meanwhile, Boston Scientific Executive Vice-President and Global Chief Medical Officer Dr Ian Meredith said: “We are pleased to bring the latest iteration of ACURATE technology to market, offering design improvements that further support procedural performance and optimal outcomes for patients with severe symptomatic aortic stenosis from those with simple to the most challenging anatomies.